Long‐term prognostic value of the H2FPEF score in patients undergoing transcatheter aortic valve implantation
Authors: Ishizu Kenichi , Shirai Shinichi , Isotani Akihiro , Hayashi Masaomi , Tabata Hiroyuki , Ohno Nobuhisa , Kakumoto Shinichi , Ando Kenji , Yashima Fumiaki , Tada Norio , Yamawaki Masahiro , Naganuma Toru , Yamanaka Futoshi , Ueno Hiroshi , Tabata Minoru , Mizutani Kazuki , Takagi Kensuke , Watanabe Yusuke , Yamamoto Masanori , Hayashida Kentaro ,   OCEAN‐TAVI Investigators
Published: April 2024

AbstractAimsA considerable proportion of candidates for transcatheter aortic valve implantation (TAVI) have underlying heart failure (HF) with preserved ejection fraction (HFpEF), which can be challenging for diagnosis because significant valvular heart disease should be excluded before diagnosing HFpEF. This study investigated the long‐term prognostic value of the pre‐procedural H2FPEF score in patients with preserved ejection fraction (EF) undergoing TAVI.Methods and resultsPatients who underwent TAVI between October 2013 and May 2017 were enrolled from the Optimized CathEter vAlvular iNtervention–Transcatheter Aortic Valve Implantation Japanese multicentre registry. After excluding 914 patients, 1674 patients with preserved EF ≥ 50% (median age: 85 years, 72% female) were selected for calculation of the H2FPEF score and were dichotomized into two groups: the low H2FPEF score [0–5 points; n = 1399 (83.6%)] group and the high H2FPEF score [6–9 points; n = 275 (16.4%)] group. Patients with high H2FPEF scores were associated with a higher prevalence of New York Heart Association Functional Class III/IV (59.3% vs. 43.7%, P < 0.001), diabetes (24.4% vs. 18.5%, P = 0.03), and paradoxical low‐flow, low‐gradient aortic stenosis (15.9% vs. 6.2%, P < 0.001). These patients showed worse prognoses than those with low H2FPEF scores regarding the cumulative 2 year all‐cause mortality (26.3% vs. 15.5%, log‐rank P < 0.001), cardiovascular mortality (10.5% vs. 5.4%, log‐rank P < 0.001), HF hospitalization (16.2% vs. 6.7%, log‐rank P < 0.001), and the composite endpoint of cardiovascular mortality and HF hospitalization (23.8% vs. 10.8%, log‐rank P < 0.001). After adjustment for several confounders, the high H2FPEF scores were independently associated with increased risk for all‐cause mortality [adjusted hazard ratio (HR), 1.48; 95% confidence interval (CI), 1.09–2.00; P = 0.011] and for the composite endpoint of cardiovascular mortality and HF hospitalization (adjusted HR, 1.95; 95% CI, 1.38–2.74; P < 0.001). Subgroup analysis confirmed the excess risk of high H2FPEF scores relative to low H2FPEF scores for the composite endpoint of cardiovascular mortality and HF hospitalization increased with a lower Society of Thoracic Surgeons (STS) score (STS score <8%: adjusted HR, 2.40; 95% CI, 1.50–3.85; P < 0.001; STS score ≥8%: adjusted HR, 1.34; 95% CI, 0.79–2.28; P = 0.28; Pinteraction = 0.030).ConclusionsThe H2FPEF score is useful for predicting long‐term adverse outcomes after TAVI, including all‐cause mortality, cardiovascular mortality, and HF hospitalization for patients with preserved EF. More aggressive interventions targeting HFpEF in addition to the TAVI procedure might be relevant in patients with high H2FPEF scores, particularly in those with a lower surgical risk.